Trends in the management of gastro-oesophageal reflux disease
- PMID: 9640439
- PMCID: PMC2360823
- DOI: 10.1136/pgmj.74.869.145
Trends in the management of gastro-oesophageal reflux disease
Abstract
Gastro-oesophageal reflux disease is common, with up to 10% of the general population experiencing heartburn on a daily basis. It is a chronic condition and follow-up studies indicate the presence of symptoms at least 20 years after initial diagnosis. In addition to lifestyle modifications, management usually involves the use of an acid suppressant from the H2-receptor antagonist or proton pump inhibitor groups or a prokinetic agent at some stage. In terms of initial symptom resolution and mucosal healing the proton pump inhibitors are consistently superior to the other available agents. However, while it is possible to keep the majority of patients in remission while taking medications, almost all patients have a recurrence of symptoms within six months of stopping medications. The introduction of laparoscopic fundoplication has produced promising initial results but the long-term benefits of this procedure remain to be established. The role of Helicobacter pylori eradication in the management of gastro-oesophageal reflux disease needs further evaluation.
Similar articles
-
Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.Clin Pharmacokinet. 1996 Nov;31(5):386-406. doi: 10.2165/00003088-199631050-00005. Clin Pharmacokinet. 1996. PMID: 9118586 Review.
-
Acid reflux and gastro-oesophageal reflux disease.Br J Community Nurs. 2004 Aug;9(8):326-30. doi: 10.12968/bjcn.2004.9.8.15353. Br J Community Nurs. 2004. PMID: 15365470 Review.
-
Gastro-oesophageal reflux disease.Lancet. 2006 Jun 24;367(9528):2086-100. doi: 10.1016/S0140-6736(06)68932-0. Lancet. 2006. PMID: 16798392 Review.
-
Treatment of gastro-oesophageal reflux disease with rabeprazole in primary and secondary care: does Helicobacter pylori infection affect proton pump inhibitor effectiveness?Aliment Pharmacol Ther. 2004 Aug 15;20(4):451-8. doi: 10.1111/j.1365-2036.2004.02096.x. Aliment Pharmacol Ther. 2004. PMID: 15298640 Clinical Trial.
-
Pharmacological management of gastro-oesophageal reflux disease.Drugs. 1995 May;49(5):695-710. doi: 10.2165/00003495-199549050-00005. Drugs. 1995. PMID: 7601011 Review.
Cited by
-
Pilot study of on-demand therapy with pantoprazole 20mg for long-term treatment in patients with mild gastro-oesophageal reflux disease.Clin Drug Investig. 2005;25(10):633-42. doi: 10.2165/00044011-200525100-00002. Clin Drug Investig. 2005. PMID: 17532708
-
Cost effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis: comparison of on-demand esomeprazole with conventional omeprazole strategies.Pharmacoeconomics. 2002;20(4):267-77. doi: 10.2165/00019053-200220040-00005. Pharmacoeconomics. 2002. PMID: 11950383
-
Pantoprazole on-demand effectively treats symptoms in patients with gastro-oesophageal reflux disease.Clin Drug Investig. 2007;27(4):287-96. doi: 10.2165/00044011-200727040-00008. Clin Drug Investig. 2007. PMID: 17358101 Clinical Trial.
-
Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders.Drugs. 2003;63(1):101-33. doi: 10.2165/00003495-200363010-00006. Drugs. 2003. PMID: 12487624 Review.
-
Medical treatment of gastro-oesophageal reflux disease.Acta Otorhinolaryngol Ital. 2006 Oct;26(5):276-80. Acta Otorhinolaryngol Ital. 2006. PMID: 17345932 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical